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S U M M A R Y
Objectives: Persistent infection with high-risk (HR) human papillomavirus (HPV) is associated with
premalignant lesions and cervical cancer, the third most common cancer amongst women globally and
the second most frequent in Egypt. We studied the prevalence and type distribution of HPV and
documented HPV infection awareness and health-related behaviours for HPV infection.
Methods: This was a multicenter, hospital-based observational study of women 18 years of age who
attended for a gynaecological examination during October 2010–August 2011. Cervical samples were
tested using Linear Array HPV genotyping. Two questionnaires on awareness and health-related
behaviour were completed.
Results: Four hundred and forty-three women with a mean age of 39.3  14.0 years were included in the
analysis. HPV DNA was detected in 10.4% of women; a single HPV-type infection was found in 6.5% and
multiple infections in 3.8%. The most prevalent HR types among HPV-positive women were HPV-16 (19.6%)
and HPV-31 and HPV-51 (15.2% each); low-risk types included HPV-62 (17.4%) and HPV-84 (10.9%). The
prevalence of HPV-18 was low (6.5%). The prevalence of any HR HPV-type was highest in women aged 45–54
years (9.2%).
Conclusions: The overall prevalence of HPV in Egypt was 10.4% and was highest (9.2%) amongst women
aged 45–54 years. These data provide important reference information for public health authorities
considering HPV prevention in Egypt.
 2014 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Persistent infection with high-risk human papillomavirus
(HPV), a sexually transmitted disease,1 is a necessary and
established cause of cervical cancer.2 This is the third most
frequent cancer in women worldwide; in 2008, an estimated
530 000 new cases were recorded and 275 000 deaths were caused
by this cancer.3 The majority of cervical cancer-related deaths
occur in developing countries,1 such as Egypt where a population§ Clinical Trial registration: NCT01158209.
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1201-9712/ 2014 Published by Elsevier Ltd on behalf of International Society for Infect
creativecommons.org/licenses/by-nc-nd/3.0/).of 25.76 million women over 15 years of age are at risk of
developing cervical cancer.4 Indeed, it has been estimated that
around 514 women are diagnosed with cervical cancer and 299 die
from the disease in Egypt each year; thus cervical cancer ranks as
the second most frequent cancer among Egyptian women.4
The epidemiological classiﬁcation of cervical cancer-associated
HPV types describes 15 as carcinogenic or high-risk (HR) (16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82) and 12 as low-
risk (LR) (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108).5 Of
these, HPV-16 and HPV-18 are the two most common HR HPV
types. They are responsible for 61% and 10%, respectively, of
cervical cancer cases worldwide, and 48% and 23%, respectively, of
cervical cancer cases in Africa.6ious Diseases. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Baseline characteristics (N = 443a)
Characteristics Categories nb n0c % 95% CI
(LL–UL)
Education level No formal
education
88 7 8.0 3.3–15.7
Primary 140 17 12.1 7.2–18.7
Secondary 143 15 10.5 6.0–16.7
Post-secondary/
university
72 7 9.7 4.0–19.0
Parity 0 87 10 11.5 5.7–20.1
1–2 153 14 9.2 5.1–14.9
3–5 183 18 9.8 5.9–15.1
6 20 4 20.0 5.7–43.7
Age at ﬁrst
marriage, years
16 20 0 0.0 0.0–16.8
17–19 173 21 12.1 7.7–18.0
20–22 155 17 11.0 6.5–17.0
23 95 8 8.4 3.7–15.9
Number of
marital partners
1 419 41 9.8 7.1–13.0
2–5 24 5 20.8 7.1–42.2
Smoking status No 422 42 10.0 7.3–13.2
Yes 21 4 19.0 5.4–41.9
95% CI, exact 95% conﬁdence interval; LL, lower limit; UL, upper limit.
a Number of subjects whose cervical samples were tested.
b Number of subjects whose cervical samples were tested and who answered the
health-related behavior questionnaire.
c Number of HPV-positive subjects in the given category.
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the world, including Egypt, to protect against HR HPV types 16 and
18: Cervarix (bivalent; GlaxoSmithKline, Belgium) and Gardasil
(quadrivalent; Merck and Co., Inc., Whitehouse Station, NJ, USA).
Both vaccines have good safety and efﬁcacy proﬁles7–11 and are
reported to provide cross-protection against non-vaccine HPV
types.12 Although both of these vaccines are already licensed in
Egypt,4 they are currently not included in the national immuniza-
tion program.13 In order to measure the impact of implementing a
nationwide policy for HPV prevention, baseline epidemiological
data are required. However, current epidemiological data for HPV
in Egyptian women are limited, and only a few publications on HPV
prevalence and attitudes towards and awareness of the infection
are available.14–16 To bridge this gap and provide baseline data, we
evaluated the prevalence and type distribution of HPV, including
HR and LR types, among Egyptian women attending routine
gynaecological examinations in different age strata, and docu-
mented awareness of HPV infection and health-related behaviours
for HPV infection.
2. Methods
2.1. Study design and population
This multicenter, observational study was carried out at two
hospitals (Al Kasr Al Aini University Hospital, Cairo, and Ain Shams
University Hospital, Cairo) and an outpatient clinic (Alexandria
University Hospital, Alexandria) between October 2010 and
August 2011. The study hospitals are tertiary university hospitals
and treat patients within their catchment areas as well as patients
from primary healthcare centres and secondary hospitals (includ-
ing regional hospitals).
Women aged 18 years undergoing routine gynaecological
examination and willing to provide a cervical sample were
enrolled. Known diagnoses of immunosuppression, previous
HPV vaccination, hysterectomy, pregnancy, or referral for an
abnormal cervical sample were all reasons for exclusion. Two
validated questionnaires were completed by all subjects en-
rolled: one on ‘health-related behaviours’ to solicit information
about smoking, marriage history (e.g., age at ﬁrst marriage),
contraception, and reproductive history (parity), and the other to
elicit information on HPV awareness, in order to assess the level
and accuracy of understanding regarding the cause, transmis-
sion, and prevention of HPV infection. These ‘knowledge–
attitudes–practices’ questionnaires were designed by a multi-
disciplinary team. The questionnaires were initially tested on
50 women in a short interview lasting for approximately 20 min
and were subsequently provided to all enrolled women by the
investigators.
2.2. Sample collection and laboratory procedures
Cervical samples were collected by a gynaecologist/trained
health practitioner using a cytobrush and placed in a liquid-based
cytology medium (Thinprep, Hologic, Inc.). A 2-ml sample was
subsequently stored at 20 8C and analyzed for the presence of
HPV DNA using Linear Array HPV genotyping at Al Mokhtabar
Laboratory, Cairo, Egypt. This technique, based on the L1 consensus
primer PGMY09/11 for PCR ampliﬁcation of HPV DNA and reverse-
line blot hybridization, was used for the detection of 37 individual
HPV genotypes.17
2.3. Statistical analyses
The primary objective was to describe the overall prevalence
and types of HPV (including multiple infections) amongwomen 18 years of age. Secondary objectives were to
investigate HPV type prevalence amongst women in different
age groups and to describe health-related behaviours. Based
on an overall HPV prevalence of 15%16 and allowing for 10% of
non-evaluable samples, to give an overall estimate of HPV
prevalence with 95% conﬁdence and a precision level of 0.035,
a total of 440 subjects were required, with at least 80 in each
age-group (18–24, 25–34, 35–44, 45–54, and 55 years of age).
The percentage of HPV-positive women in each category was
tabulated with corresponding exact 95% conﬁdence intervals
(CI). A description of subject characteristics (i.e., educational
level, age at ﬁrst marriage, number of marital partners, parity,
and smoking status) and HPV status is provided, including the
95% conﬁdence intervals for the prevalence of these character-
istics. All statistical analyses were undertaken using SAS version
9.2 statistical analysis software.
2.4. Ethical considerations
The study was approved by the National Ethics Committee
of the Egyptian Ministry of Health and was conducted in
accordance with the Declaration of Helsinki and the International
Conference on Harmonization Guidelines for Good Clinical
Practice. Informed consent was obtained from all eligible women
before starting the study.
3. Results
3.1. Study population
Of the 1156 women aged 18 years who visited the practice, a
total of 490 provided a cervical sample and were enrolled in the
study. Cervical samples were not collected or tested in 47 cases,
leaving 443 women in the ﬁnal analysis, all of whom completed
both questionnaires. The mean  standard deviation (SD) age of
women was 39.3  14.0 years and the majority (78.6%) lived in urban
areas. The baseline characteristics of women enrolled in the study are
shown in Table 1.
Figure 1. HPV type distribution among women with a single or multiple HPV type
infection by age (N = 443; number of subjects whose cervical samples were tested).
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HPV DNA was detected in 10.4% (46/443) of women, of
whom 6.5% were infected with a single HPV type and 3.8% with
multiple HPV types. The overall prevalence of any HR HPV
type was 6.5% (predominantly HPV-16 (2.0%), HPV-31 (1.6%), and
HPV-51 (1.6%)) compared with 5.0% for any LR HPV type
(predominantly HPV-62 (1.8%), HPV-84 (1.1%), and HPV-6
(0.7%)) (Table 2).
3.3. HPV prevalence and type distribution among HPV-positive
women
The prevalence of any HR HPV type was 63.0% (95% CI 47.5–
76.8; 29/46) and the prevalence of any LR HPV type was 47.8%
(95% CI 32.9–63.1; 22/46).
The most prevalent HR HPV types were HPV-16 (19.6%), HPV-31
and HPV-51 (15.2%, each), and HPV-52 (13.0%). LR HPV types
HPV-62 (17.4%), HPV-84 (10.9%), and HPV-6 (6.5%) were prevalent
among women positive for HPV. The prevalence of HPV-18 was
low (6.5%).
3.4. HPV prevalence and type distribution by age
The overall prevalence of HPV infection was highest (13.2%,
12/91) in women aged 18–24 years. The prevalence of any HR
HPV type was highest (9.2%, 8/87) in the 45–54 years age group,
while the prevalence of any LR HPV type was highest (9.2%, 8/87)
in women aged 35–44 years (Figure 1).
The type distribution of HPV by age is summarized in
Table 3. The highest number of HR HPV type 16 infections was
observed in women aged 55 years, followed by those in the
18–24 years age group.Table 2
HPV prevalence and type distribution (N = 443a)
HPV prevalence/types nb %c 95% CI (LL–UL)
HPV-negative 397 89.6 86.4–92.3
HPV-positive 46 10.4 7.7–13.6
Single infection 29 6.5 4.4–9.3
Multiple infections 17 3.8 2.3–6.1
Any high-risk HPV 29 6.5 4.4–9.3
HPV-16 9 2 0.9–3.8
HPV-31 7 1.6 0.6–3.2
HPV-51 7 1.6 0.6–3.2
HPV-52 6 1.4 0.5–2.9
HPV-59 5 1.1 0.4–2.6
HPV-18 3 0.7 0.1–2
HPV-58 3 0.7 0.1–2
HPV-66 2 0.5 0.1–1.6
HPV-56 1 0.2 0–1.3
HPV-73 1 0.2 0–1.3
Any low-risk HPV 22 5 3.1–7.4
HPV-62 8 1.8 0.8–3.5
HPV-84 5 1.1 0.4–2.6
HPV-6 3 0.7 0.1–2
HPV-40 2 0.5 0.1–1.6
HPV-CP6108 2 0.5 0.1–1.6
HPV-26 1 0.2 0–1.3
HPV-53 1 0.2 0–1.3
HPV-61 1 0.2 0–1.3
HPV-67 1 0.2 0–1.3
HPV-70 1 0.2 0–1.3
HPV-81 1 0.2 0–1.3
HPV-83 1 0.2 0–1.3
HPV, human papillomavirus; 95% CI, exact 95% conﬁdence interval; LL, lower limit;
UL, upper limit.
a Number of subjects whose cervical samples were tested.
b Number of subjects in a given category.
c b/number of subjects with available results  100.3.5. HPV co-infection
Overall, 37.0% (17/46) of HPV-positive women were co-infected
with more than one HPV type. Four out of nine HPV-16-positive
women (44.4%) were co-infected with other HR HPV types and one
out of three HPV-18-positive women (33.3%) was co-infected with
other HR HPV types.
3.6. HPV prevalence by risk factors
Data derived from the completed questionnaires indicated that
most women (90.1%) were married; 32.3% had received secondary
education and 16.3% had undertaken post-secondary/university
level education (Table 1).
The assessment of health-related behaviours (age at ﬁrst
marriage, number of marital partners, parity, education, and
smoking status) did not show major differences between HR and
LR HPV infections (Table 1).
3.7. HPV awareness questionnaire
The awareness questionnaire indicated that 33.2% of women
had previously received information about HPV and almost 99%
expressed an interest in vaccination (Table 4).
4. Discussion
This is the most recent study to estimate the prevalence and
type distribution of HPV in Egyptian women aged at least 18 years.
In our study, conducted at three large hospitals, 10.4% of women
attending routine gynaecological examinations were found to
be HPV-positive, which is comparable to the overall prevalence
reported previously in Egypt (10.3%4 and 15%16), Northern Africa
(10.9%),18 and globally (11.4%).4
In this study, HPV-16, 31, and 51 were the most prevalent HR
HPV types, and HPV-62, 84, and 6 were the most prevalent LR HPV
types, which is consistent with the global circulating HPV types.6,18
In contrast to the worldwide estimates that HPV-16 and 18 are
responsible for nearly 70% of cervical cancer cases,6 our study
showed a relatively low (0.7%) prevalence of HPV-18 in Egyptian
women.
Our study found that the prevalence of HR HPV types was
highest in women aged 45–54 years, which is consistent with
the global trend of higher disease burden in older women.18
We also noted a higher prevalence of HR-HPV type 16 in women
Table 3
Distribution of HPV types among subjects with single or multiple HPV infections by age (N = 443a)
HPV types 18–24 years (nb = 91) 25–34 years (n = 90) 35–44 years (n = 87) 45–54 years (n = 87) 55 years (n = 88)
n0c %d 95% CI
(LL–UL)
n0 % 95% CI (LL–UL) n0 % 95% CI
(LL–UL)
n0 % 95% CI
(LL–UL)
n0 % 95% CI
(LL–UL)
Any high-risk HPV 7 7.7 3.1–15.2 7 7.8 3.2–15.4 2 2.3 0.3–8.1 8 9.2 4.1–17.3 5 5.7 1.9–12.8
HPV-16 3 3.3 0.7–9.3 1 1.1 0–6 1 1.1 0–6.2 1 1.1 0–6.2 3 3.4 0.7–9.6
HPV-18 1 1.1 0–6 0 0 0–4 0 0 0–4.2 1 1.1 0–6.2 1 1.1 0–6.2
HPV-31 1 1.1 0–6 1 1.1 0–6 1 1.1 0–6.2 4 4.6 1.3–11.4 0 0 0–4.1
HPV-51 3 3.3 0.7–9.3 1 1.1 0–6 0 0 0–4.2 2 2.3 0.3–8.1 1 1.1 0–6.2
HPV-52 0 0 0–4 1 1.1 0–6 1 1.1 0–6.2 4 4.6 1.3–11.4 0 0 0–4.1
HPV-56 1 1.1 0–6 0 0 0–4 0 0 0–4.2 0 0 0–4.2 0 0 0–4.1
HPV-58 1 1.1 0–6 2 2.2 0.3–7.8 0 0 0–4.2 0 0 0–4.2 0 0 0–4.1
HPV-59 1 1.1 0–6 3 3.3 0.7–9.4 1 1.1 0–6.2 0 0 0–4.2 0 0 0–4.1
HPV-66 0 0 0–4 1 1.1 0–6 0 0 0–4.2 1 1.1 0–6.2 0 0 0–4.1
HPV-73 0 0 0–4 0 0 0–4 0 0 0–4.2 1 1.1 0–6.2 0 0 0–4.1
Any low-risk HPV 7 7.7 3.1–15.2 0 0 0–4 8 9.2 4.1–17.3 4 4.6 1.3–11.4 3 3.4 0.7–9.6
HPV-6 1 1.1 0–6 0 0 0–4 0 0 0–4.2 0 0 0–4.2 2 2.3 0.3–8
HPV-26 0 0 0–4 0 0 0–4 1 1.1 0–6.2 0 0 0–4.2 0 0 0–4.1
HPV-40 1 1.1 0–6 0 0 0–4 0 0 0–4.2 1 1.1 0–6.2 0 0 0–4.1
HPV-53 0 0 0–4 0 0 0–4 0 0 0–4.2 1 1.1 0–6.2 0 0 0–4.1
HPV-61 0 0 0–4 0 0 0–4 1 1.1 0–6.2 0 0 0–4.2 0 0 0–4.1
HPV-62 4 4.4 1.2–10.9 0 0 0–4 1 1.1 0–6.2 2 2.3 0.3–8.1 1 1.1 0–6.2
HPV-67 0 0 0–4 0 0 0–4 1 1.1 0–6.2 0 0 0–4.2 0 0 0–4.1
HPV-70 0 0 0–4 0 0 0–4 1 1.1 0–6.2 0 0 0–4.2 0 0 0–4.1
HPV-81 1 1.1 0–6 0 0 0–4 0 0 0–4.2 0 0 0–4.2 0 0 0–4.1
HPV-83 0 0 0–4 0 0 0–4 1 1.1 0–6.2 0 0 0–4.2 0 0 0–4.1
HPV-84 2 2.2 0.3–7.7 0 0 0–4 2 2.3 0.3–8.1 1 1.1 0–6.2 0 0 0–4.1
HPV-CP6108 0 0 0–4 0 0 0–4 2 2.3 0.3–8.1 0 0 0–4.2 0 0 0–4.1
95% CI, exact 95% conﬁdence interval; LL, lower limit; UL, upper limit.
a Number of subjects whose cervical samples were tested.
b Number of subjects who underwent cervical sample testing in each age stratum.
c Number of subjects infected with a given HPV type.
d c/b  100.
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reports, where the mean age of women with cervical cancer
caused by HPV-16 is 50.0 years.6 However, further testing of the
cervical specimens might be required to ascertain if these women
have cervical diseases.
Analysis of the health-related behaviour questionnaire
revealed that age at ﬁrst marriage, number of lifetime partners,
parity, and smoking status were not reported more frequently
for HPV-16, HPV-18, or any HR HPV infection. A previously
conducted two-series study by the International Agency for
Research on Cancer observed no association between education
level and HPV infection.19 Although 19.9% (88/443) of women
included in the present study had not received any formal
education, HPV prevalence among these women was low (8%),
while the prevalence was higher in those who had received
primary, secondary, or post-secondary/university education
(12.1%, 11.0%, and 9.7%, respectively); however, all 95% CI
overlapped, thus strong conclusions on the difference cannot
be drawn.
Data from the HPV awareness questionnaire indicated that
few women (33.2%) had previously heard of HPV. These
ﬁndings are consistent with previous studies that noted a low
awareness of HPV and its link to cervical cancer amongst
Egyptian women. Indeed, only about 1.5% of women from
urban areas have routine Pap tests.14 Of interest is that almost
all women who completed the questionnaire expressed an
interest in vaccination.
In 2006, the Middle East Cancer Consortium published
statistics from four Middle Eastern countries (Egypt, Jordan,
Cyprus, and Israel) on population-based registry data.20 The
Tanta registry for Egypt (1999–2001) reported an age-adjusted
standardized incidence rate of 2.7 for cervical cancer compared
with the higher rates of 5.3 in Israeli Jews and 3.7 in Cypriots
and the lower rates of 2.6 in Jordanians and 2.5 in Israeli Arabs
(per 100 000 females).20 Data from Globocan estimated theage-standardized incidence and mortality rates per 100 000
females for cervical cancer in Egypt as 1.6 and 1.3, respectively,
as compared with 6.6 and 4.0, respectively, in North Africa and
9.0 and 5.8, respectively, in the Eastern Mediterranean region.21
Although these data indicate that the rates of incidence of
cervical cancer and the associated mortality are lower in Egypt
than in some of the neighbouring countries,20,21 cervical cancer
indeed causes a substantial disease burden in Egypt. In addition,
since the detection rate of cervical cancer at an early stage
(stage I and/or II) in Egypt is much lower (36%) as compared to
that in the USA (60%),22 there is a possibility of some cervical
cancer cases and deaths not being reported or diagnosed.
Therefore early detection and preventive strategies are necessary
to reduce the disease burden of cervical cancer in Egypt.
Both the bivalent and quadrivalent vaccines provide protec-
tion against HR HPV-16 and HPV-18 and have been reported to
provide cross-protection against non-vaccine HR HPV-31, 33, 45,
52, or 58.7–12 Since we found additional HR HPV types circulating
in the country, cross-protective properties of these vaccines might
protect Egyptian women from cervical cancers and pre-cancer
lesions.
Our study had some limitations. Firstly, the study was cross-
sectional, and as HPV infections may be transient and resolve on
their own, the prevalence of HPV might therefore change over
time. Secondly, since the cervical samples were collected only from
women attending routine gynaecological visits, there is a
possibility of selection bias. Lastly, since the number of women
positive for HPV infection was indeed low (n = 46), our results need
to be interpreted with caution.
Despite these limitations, the study had several strengths. The
high quality DNA testing at a single laboratory using a
standardized test for all samples ensured the collection of robust
data while avoiding variability across different laboratories. Also,
this was a multicentre study conducted in three large hospitals.
The participating hospitals were tertiary university hospitals
Table 4
Awareness of HPV infection among subjects (N = 443a)
Characteristics Categories nb %c
How frequent is cervical cancer in women? Very frequent 71 16.0
Frequent 94 21.2
Rare 210 47.4
Not sure 67 15.1
Missing 1 0.2
What do you think is/are the main reasons for cervical cancer?d Abnormal cells growing inside the body 79 17.8
Bacterial infection 54 12.2
Viral infection 144 32.5
None 52 11.7
Not sure 114 25.7
Which among these can cause cervical cancer?d Persistent infection with HPV 44 9.9
Rous sarcoma virus 13 2.9
Hereditary/genetic factors 242 54.6
None 37 8.4
Not sure 107 24.2
What do you think can turn into cervical cancerd Genital warts 88 19.9
Bacterial infection 43 9.7
Viral infection 113 25.5
Fungal infection 41 9.3
None 51 11.5
Not sure 107 24.2
Apart from avoiding unwanted pregnancy, what would you
think can happen with the use of contraceptive pillsd
Protects against cervical cancer 79 17.8
Increases the risk of cervical cancer 68 15.3
No ill effect at all 66 14.9
Not sure 230 51.9
Did you hear about HPV before? Yes 147 33.2
No 296 66.8
If yesd General physician 33 7.4
Friend or family member 41 9.3
Internet 32 7.2
TV/magazine/newspaper 41 9.3
How is HPV transmitted?d Contaminated food/water 80 18.1
Mosquito bite 32 7.2
Sexually 98 22.1
None 38 8.6
Not sure 192 43.3
How is cervical cancer diagnosed?d Pap smear test (Papanicolaou test) 30 6.8
Colposcopy 22 5.0
Biopsy sample testing (histological) 186 42.0
All above 43 9.7
None 18 4.1
Not sure 144 32.5
Is it possible to prevent cervical cancer? Yes 125 28.2
No 167 37.7
Not sure 151 34.1
If yesd Through cancer vaccine 25 5.6
Through responsible sexual behavior 22 5.0
Through cervical screening 47 10.6
Through condom use 31 7.0
If the vaccine against cervical cancer was available,




a Number of subjects whose cervical samples were tested.
b Number of subjects in the speciﬁed category for whom the questionnaire data were collected.
c Percentage of subjects in the speciﬁed category for whom the questionnaire data were collected.
d Subjects could have selected more than one option.
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questionnaires were completed by all enrolled women and
therefore provided a good dataset for analysis.
In conclusion, the results from our study provide important
reference data for public health ofﬁcials when formulating future
strategies, including vaccination programs, to prevent HPV-
associated complications in Egypt. Further analysis on the
potential health and economic impact of preventive actions will
be necessary to complement our data.
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